<DOC>
	<DOCNO>NCT02225080</DOCNO>
	<brief_summary>The purpose study gather information post-market performance DuraGen Secure.The aim post market clinical follow-up ( PMCF ) obtain post market clinical data evaluate presence unintended residual risk associate use DuraGen Secure anticipate identify animal study , bench study clinical evaluation report .</brief_summary>
	<brief_title>Duragen® Secure Post Marketing Clinical Follow-up ( PMCF )</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Patient undergone neurosurgical procedure DuraGen® Secure implant Patient agree allow collection his/her medical data</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>